B+
Bull case
25%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
LRMR
Larimar TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$4.70
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.80
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-17
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+83.4
Score
AI commentary
Primary-company and SEC evidence is constructive on regulatory and clinical milestones, but safety and approval uncertainty remain significant. The Q2 update included an EPS beat, while verified market reaction and analyst revisions are unavailable. Social coverage is absent, supporting a cautious monitoring stance rather than a high-conviction bullish view.
RankAlpha Sentiment Codex - 2026-08-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-31catalystQ2 update showed an EPS beat, but post-print confirmation is limitedMedium impact
The stored Q2 earnings context reports a $0.30 per-share loss versus a $0.39 Zacks estimate; however, verified post-release price attribution and analyst revisions are unavailable [#PR-EARNINGS-2026-08-04].
2026-09-30eventGlobal confirmatory Phase 3 initiationHigh impact
The company expects to dose the first patient in its global confirmatory Phase 3 study in Q3 2026, creating an execution checkpoint for nomlabofusp [#SEC-8K-2026-08-04].
2026-12-31eventRolling BLA completion and FDA review progressionHigh impact
Larimar submitted the first module of a rolling BLA seeking accelerated approval after a Type B pre-BLA meeting, with completion expected in the second half of 2026. Approval remains uncertain [#SEC-8K-2026-08-04].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-17 • Updated nightlySource: Internal modelMethodology